المؤلفون: Horowitz NS; Brigham and Women's Hospital/Dana-Farber Cancer Institute., Deng W; NRG Oncology/Gynecologic Oncology Group Statistics & Data Center, Buffalo, NY., Peterson I; Mayo Clinic, Rochester, MN., Mannel RS; University of Oklahoma Health Sciences Center, Oklahoma City, OK., Thompson S; University of Oklahoma Health Sciences Center, Oklahoma City, OK., Lokich E; Women's and Infants Hospital, Providence, RI., Myers T; Bay State Health, Springfield, MA., Hanjani P; Abington Health, Abington, PA., O'Malley DM; The James CCC & The Ohio State University Wexner Medical Center, Columbus, OH., Chung KY; Prisma Health Cancer Institute, Greenville, SC., Miller DS; University of Texas Southwestern Medical Center, Dallas, TX., Ueland FR; University of Kentucky College of Medicine, Lexington, KY., Dizon DS; Lifespan, Providence, RI., Miller A; NRG Oncology/Gynecologic Oncology Group Statistics & Data Center, Buffalo, NY., Mayadev JS; University of California San Diego School of Medicine, La Jolla, CA., Leath CA 3rd; O'Neal Comprehensive Cancer Center at the University of Alabama Birmingham; Birmingham, AL., Monk BJ; GOG Partners at The GOG Foundation Inc, Phoenix, AZ.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 01; Vol. 42 (16), pp. 1914-1921. Date of Electronic Publication: 2024 Apr 04.

نوع المنشور: Journal Article; Clinical Trial, Phase II

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Vulvar Neoplasms*/pathology , Vulvar Neoplasms*/radiotherapy , Vulvar Neoplasms*/drug therapy , Vulvar Neoplasms*/mortality , Vulvar Neoplasms*/therapy , Radiotherapy, Intensity-Modulated*/methods , Radiotherapy, Intensity-Modulated*/adverse effects , Cisplatin*/administration & dosage , Cisplatin*/therapeutic use , Gemcitabine* , Carcinoma, Squamous Cell*/pathology , Carcinoma, Squamous Cell*/therapy , Carcinoma, Squamous Cell*/radiotherapy , Carcinoma, Squamous Cell*/mortality , Carcinoma, Squamous Cell*/drug therapy , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Middle Aged ; Adult ; Chemoradiotherapy/methods ; Progression-Free Survival

المؤلفون: Nakamura Y; National Cancer Center Hospital East, Kashiwa, Japan., Mizuno N; Aichi Cancer Center Hospital, Nagoya, Japan., Sunakawa Y; St Marianna University Hospital, Kawasaki, Japan., Canon JL; Grand Hospital de Charleroi, Charleroi, Belgium., Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN., Hayashi H; Kindai University Hospital, Osakasayama, Japan., Jerusalem G; CHU de Liege and Liege University, Liege, Belgium., Kim ST; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea., Lee KW; Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea., Kankeu Fonkoua LA; Mayo Clinic Rochester, Rochester, MN., Monk BJ; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ., Nguyen D; City of Hope National Medical Center, Duarte, CA., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Okines A; The Royal Marsden NHS Foundation Trust, London, UK., O'Malley DM; The Ohio State University & James Comprehensive Cancer Center, Columbus, OH., Pohlmann P; MD Anderson Cancer Center, Houston, TX., Reck M; Department of Thoracic Oncology, Airway Research Center North, Germany Center for Lung Disease, Grosshansdorf, Germany., Shin SJ; Severance Hospital, Yonsei University Health System, Seoul, South Korea., Sudo K; National Cancer Center, Tokyo, Japan., Takahashi S; Cancer Institute Hospital of JFCR, Tokyo, Japan., Van Marcke C; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Yu EY; Fred Hutchinson Cancer Center/University of Washington, Seattle, WA., Groisberg R; Merck & Co, Inc, Rahway, NJ., Ramos J; Seagen Inc, Bothell, WA., Tan S; Seagen Inc, Bothell, WA., Stinchcombe TE; Duke Cancer Institute, Durham, NC., Bekaii-Saab T; Mayo Clinic Scottsdale, Scottsdale, AZ.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 20; Vol. 41 (36), pp. 5569-5578. Date of Electronic Publication: 2023 Sep 26.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/adverse effects , Neoplasms*/drug therapy, Humans ; Trastuzumab/adverse effects ; Receptor, ErbB-2/metabolism ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Monk BJ; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Fujiwara K; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., O'Malley DM; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Coleman RL; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., McNeish IA; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Lin KK; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Hume S; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Kristeleit RS; Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Feb 01; Vol. 41 (4), pp. 936-938. Date of Electronic Publication: 2022 Oct 06.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Copeland LJ; The Ohio State University, James Cancer Hospital, Columbus, OH., Brady MF; Roswell Park Comprehensive Cancer Center, State University of New York at Buffalo, Buffalo, NY., Burger RA; University of Pennsylvania, Philadelphia, PA., Rodgers WH; Weill Cornell Medical College, New York, NY., Huang HQ; Roswell Park Comprehensive Cancer Center, State University of New York at Buffalo, Buffalo, NY., Cella D; Northwestern University, Chicago, IL., O'Malley DM; The Ohio State University, James Cancer Hospital, Columbus, OH., Street DG; The University of Oklahoma, Oklahoma City, OK., Tewari KS; UC Irvine Medical Center, Orange, CA., Bender DP; University of Iowa Hospitals and Clinics, Iowa City, IA., Morris RT; Barbara Ann Karmanos Cancer Institute, Detroit, MI., Lowery WJ; Murtha Cancer Center, Walter Reed National Military Medical Center, Chicago, IL., Miller DS; The University of Texas Southwestern Medical Center, Dallas, TX., Dewdney SB; Rush University Medical Center, Chicago, IL., Spirtos NM; Women's Cancer Center, Las Vegas, NV., Lele SB; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Guntupalli S; University of Colorado Denver, Aurora, CO., Ueland FR; University of Kentucky Medical Center, Lexington, KY., Glaser GE; Carilion Clinic, Roanoke, VA., Mannel RS; The University of Oklahoma, Oklahoma City, OK., DiSaia PJ; UC Irvine Medical Center, Orange, CA.; Deceased.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Dec 10; Vol. 40 (35), pp. 4119-4128. Date of Electronic Publication: 2022 Jun 27.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Platinum* , Neoplasms*, Female ; Humans ; Medical Futility

المؤلفون: Monk BJ; GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ., Parkinson C; Medical Oncology, Addenbrooke's Hospital, Cambridge, United Kingdom., Lim MC; Gynecologic Oncology, National Cancer Center Korea, Goyang-si, Gyeonggi-do, South Korea., O'Malley DM; Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Wilson MK; Department of Cancer and Blood, Auckland City Hospital, Auckland, New Zealand., Coleman RL; US Oncology Research, The Woodlands, TX., Lorusso D; MITO and Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy., Bessette P; Department of Obstetrics and Gynecology, University of Sherbrooke, Sherbrooke, Quebec, Canada., Ghamande S; Department of Obstetrics and Gynecology, Augusta University, Augusta, GA., Christopoulou A; Medical Oncology, St Andrews General Hospital, Patras, Greece., Provencher D; Princess Margaret Consortium and Department of Obstetrics-Gynaecology, Centre Hospitalier de l'Université de Montréal (CHUM), Institut du Cancer de Montréal, Montréal, Canada., Prendergast E; Gynecologic Oncology, Minnesota Oncology and Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN., Demirkiran F; Gynecologic Oncology Department, Medical Faculty, Istanbul University, Cerrahpaşa, Istanbul, Turkey., Mikheeva O; Limited Liability Company MedPomosch, Saint Petersburg, Russia., Yeku O; Gynecologic Cancers Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA., Chudecka-Glaz A; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland., Schenker M; Department of Medical Oncology, Sfantul Nectarie Oncology Center, Dolj, Romania., Littell RD; Kaiser Permanente Northern California Gynecologic Cancer Program, San Francisco, CA., Safra T; Oncology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Chou HH; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital (Linkou), Tao-Yuan, Taiwan.; College of Life Science, National Tsing Hua University, Hsinchu, Taiwan., Morgan MA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA., Drochýtek V; Department of Obstetrics and Gynaecology, Faculty Hospital Kralovske Vinohrady, 3rd Medical Faculty, Charles University, Prague, Czech Republic., Barlin JN; Women's Cancer Care Associates, Division of Gynecologic Oncology, Albany Medical College, Albany, NY., Van Gorp T; Division of Gynaecological Oncology, Department of Obstetrics and Gynecology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Ueland F; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Kentucky, Lexington, KY., Lindahl G; Nordic Society of Gynaecological Oncology, Copenhagen, Denmark.; Department of Oncology, Linköping University, Linköping, Sweden., Anderson C; Department of Gynecologic Oncology, Willamette Valley Cancer Institute and Research Center, Eugene, OR., Collins DC; Cancer Trials Ireland and Department of Medical Oncology, Cork University Hospital, Cork, Ireland., Moore K; Stevenson Cancer Center at the University of Oklahoma Health Sciences Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK., Marme F; AGO and Department Obstetrics and Gynecology, University Hospital Mannheim, Mannheim, Germany., Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., McNeish IA; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Shih D; Clinical Operations, Clovis Oncology Inc, Boulder, CO., Lin KK; Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO., Goble S; Biostatistics, Clovis Oncology Inc, Boulder, CO., Hume S; Clinical Development, Clovis Oncology Inc, Boulder, CO., Fujiwara K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan., Kristeleit RS; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Dec 01; Vol. 40 (34), pp. 3952-3964. Date of Electronic Publication: 2022 Jun 06.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*/adverse effects , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/surgery, Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Indoles/adverse effects ; Maintenance Chemotherapy

المؤلفون: O'Malley DM; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, OH., Bariani GM; Department of Medical Oncology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Marabelle A; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Institut National de la Santé et de la Recherche Médicale (INSERM U1015), Gustave Roussy, Université Paris Saclay, Villejuif, France., Hansen AR; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., De Jesus Acosta A; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., Miller WH Jr; Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada.; Departments of Oncology and Medicine, McGill University, Montreal, QC, Canada., Safra T; Oncology Department, Tel Aviv Medical Center, Tel Aviv, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonie, Bordeaux, France.; Faculty of Medicine, University of Bordeaux, France., Mileshkin L; Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia., Xu L; Merck & Co, Inc, Kenilworth, NJ., Jin F; Merck & Co, Inc, Kenilworth, NJ., Norwood K; Merck & Co, Inc, Kenilworth, NJ., Maio M; Division of Medical Oncology and Immunotherapy, Center for Immuno-Oncology, Department of Oncology, University Hospital of Siena, Siena, Italy.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Mar 01; Vol. 40 (7), pp. 752-761. Date of Electronic Publication: 2022 Jan 06.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: DNA Mismatch Repair* , Microsatellite Instability*, Antibodies, Monoclonal, Humanized/*therapeutic use , Antineoplastic Agents, Immunological/*therapeutic use , Biomarkers, Tumor/*genetics , Endometrial Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Endometrial Neoplasms/genetics ; Endometrial Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Non-Randomized Controlled Trials as Topic ; Prognosis ; Retrospective Studies ; Survival Rate

المؤلفون: O'Malley DM; Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH., Neffa M; CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine., Monk BJ; Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ., Melkadze T; Research Institute of Clinical Medicine, Tbilisi, Georgia., Huang M; Division of Gynecologic Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL., Kryzhanivska A; Regional Clinical Oncology Center, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine., Bulat I; ARENSIA Exploratory Medicine Unit, Institute of Oncology, Chisinau, Moldova., Meniawy TM; Linear Clinical Research, Nedlands, Australia., Bagameri A; Országos Onkológiai Intézet, Budapest, Hungary., Wang EW; Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA., Doger de Speville Uribe B; START Madrid FJD, Madrid, Spain., Hegg R; Clínica de Pesquisa e Centro de Estudos em Oncologia Ginecológica e Mamária, Sao Paulo, Brazil., Ortuzar Feliu W; Agenus Inc, Waltham, MA., Ancukiewicz M; Agenus Inc, Waltham, MA., Lugowska I; Maria Sklodowska-Curie National Research Unit of Oncology, Warsaw, Poland.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Mar 01; Vol. 40 (7), pp. 762-771. Date of Electronic Publication: 2021 Dec 21.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , CTLA-4 Antigen/*antagonists & inhibitors , Immune Checkpoint Inhibitors/*therapeutic use , Neoplasm Recurrence, Local/*drug therapy , Programmed Cell Death 1 Receptor/*antagonists & inhibitors , Uterine Cervical Neoplasms/*drug therapy, Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Survival Rate ; Uterine Cervical Neoplasms/immunology ; Uterine Cervical Neoplasms/pathology ; Young Adult

المؤلفون: Oonk MHM; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Slomovitz B; Mount Sinai Medical Center, Miami Beach, FL., Baldwin PJW; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., van der Velden J; Amsterdam University Medical Center, Amsterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Leiden, the Netherlands., Slangen BFM; Maastricht University Medical Center+, Maastricht, the Netherlands., Vergote I; Leuven Cancer Institute, Leuven, Belgium., Brännström M; Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden., van Dorst EBL; University Medical Center Utrecht, Utrecht, the Netherlands., van Driel WJ; Center of Gynecological Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hermans RH; Catharina Ziekenhuis Eindhoven, the Netherlands., Nunns D; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Widschwendter M; UCL EGA Institute for Women's Health, University College London, London, United Kingdom., Nugent D; Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, United Kingdom., Holland CM; Manchester University NHS Foundation Trust-St Marys Hospital, Manchester, United Kingdom., Sharma A; University Hospital of Wales, Cardiff, United Kingdom., DiSilvestro PA; Women and Infants Hospital of Rhode Island, Providence, RI., Mannel R; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK., Boll D; Catharina Ziekenhuis Eindhoven, the Netherlands., Cibula D; First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic., Covens A; University of Toronto, Toronto, Ontario, Canada., Provencher D; CHUM, Université de Montréal, Montréal, Quebec, Canada., Runnebaum IB; Jena University Hospital, Friedrich Schiller University, Jena, Germany., Luesley D; University of Birmingham, Birmingham, United Kingdom., Ellis P; Royal Surrey NHS Foundation Trust, Guildford, United Kingdom., Duncan TJ; Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom., Tjiong MY; Amsterdam University Medical Center, Amsterdam, the Netherlands., Cruickshank DJ; James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, United Kingdom., Kjølhede P; Linköping University, Linköping, Sweden., Levenback CF; MD Anderson Cancer Center, Houston, TX., Bouda J; University Hospital Pilsen, Charles University, Faculty of Medicine, Pilsen, Czech Republic., Kieser KE; Dalhousie University, Halifax, Nova Scotia, Canada., Palle C; Capio, Part of Ramsey Santé, Hellerup, Denmark., Spirtos NM; Women's Cancer Center of Nevada, Las Vegas, NV., O'Malley DM; Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH., Leitao MM; Memorial Sloan Kettering Cancer Center, New York, NY., Geller MA; University of Minnesota, Minneapolis, MN., Dhar K; Singleton Hospital, Swansea, United Kingdom., Asher V; University Hospitals of Derby and Burton, Derby, United Kingdom., Tamussino K; Medical University Graz, Graz, Austria., Tobias DH; Morristown Medical Center, Morristown, NJ., Borgfeldt C; Skåne University Hospital, Lund University, Lund, Sweden., Lea JS; UT Southwestern Medical Center, Dallas, TX., Bailey J; St Michaels Hospital, Bristol, United Kingdom., Lood M; Central Hospital Karlstad, Karlstad, Sweden., Eyjolfsdottir B; Oslo University Hospital, Radiumhospitalet, Oslo, Norway., Attard-Montalto S; West Kent Cancer Centre, Maidstone Hospital, Maidstone, United Kingdom., Tewari KS; UC Irvine Health Medical Center, Orange, CA., Manchanda R; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom., Jensen PT; Aarhus University Hospital, Aarhus, Denmark., Persson P; Uppsala University, Uppsala, Sweden., Van Le L; University of North Carolina, Chapel Hill, NC., Putter H; Leiden University Medical Center, Leiden, the Netherlands., de Bock GH; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Monk BJ; St Josephs Hospital and Medical Center, Phoenix, AZ., Creutzberg CL; Leiden University Medical Center, Leiden, the Netherlands., van der Zee AGJ; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 10; Vol. 39 (32), pp. 3623-3632. Date of Electronic Publication: 2021 Aug 25.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Webcast

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lymph Node Excision*/adverse effects , Lymph Node Excision*/mortality , Radiation Dosage*, Sentinel Lymph Node/*radiation effects , Sentinel Lymph Node/*surgery , Vulvar Neoplasms/*therapy, Aged ; Female ; Humans ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Micrometastasis ; Neoplasm Staging ; Prospective Studies ; Sentinel Lymph Node/pathology ; Time Factors ; Treatment Outcome ; Vulvar Neoplasms/mortality ; Vulvar Neoplasms/pathology

المؤلفون: Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ., Grisham RN; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY., Banerjee S; Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, United Kingdom., Kalbacher E; Centre Hospitalier Régional et Universitaire de Besançon, CHRU de Besançon, Besançon, France., Mirza MR; Nordic Society of Gynaecological Oncology and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Romero I; Servicio de Oncologıa Medica, Fundacion Instituto Valenciano de Oncologıa, Valencia, Spain., Vuylsteke P; CHU Université catholique de Louvain Namur, Sainte-Elisabeth, Namur, Belgium.; University of Botswana, Gaborone, Botswana., Coleman RL; MD Anderson Cancer Center, Houston, TX., Hilpert F; Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany., Oza AM; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Westermann A; Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Oehler MK; Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia., Pignata S; Istituto Nazionale Tumori Fondazione Pascale IRCCS, Naples, Italy., Aghajanian C; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ., Colombo N; Dipartimento Medicina e Chirurgia, Università Milano-Bicocca, Programma Ginecologia Oncologica Istituto Europeo Oncologia, IRCCS, Milan, Italy., Drill E; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY., Cibula D; First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Moore KN; Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK., Christy-Bittel J; Pfizer, New York, NY., Del Campo JM; Vall d'Hebron University Hospital, Barcelona, Spain., Berger R; University Clinic for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck 6020, Austria., Marth C; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Austrian AGO, Innsbruck, Austria., Sehouli J; Center for Oncological Surgery, European Competence Center for Ovarian Cancer Campus Virchow Klinikum and Benjamin Franklin Charité Comprehensive Cancer Center , Medical University of Berlin, Berlin, Germany., O'Malley DM; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH., Churruca C; Biodonostia HRI, Osasun Ikerketa Insitutua, Insituto de Investigacion Sanitaria, San Sebastián, Gipuzkoa, Spain., Boyd AP; Pfizer, New York, NY., Kristensen G; Department for Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Clamp A; Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, United Kingdom., Ray-Coquard I; Centre Léon Bérard, Netsarc Network, Université Claude Bernard Lyon 1, Lyon, France., Vergote I; Belgium and Luxemburg Gynaecological Oncology Group, University Hospitals Leuven, Leuven, Belgium.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 10; Vol. 38 (32), pp. 3753-3762. Date of Electronic Publication: 2020 Aug 21.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Benzimidazoles/*therapeutic use , Cystadenocarcinoma, Serous/*drug therapy , Fallopian Tube Neoplasms/*drug therapy , Ovarian Neoplasms/*drug therapy , Peritoneal Neoplasms/*drug therapy , Protein Kinase Inhibitors/*therapeutic use, Adult ; Aged ; Benzimidazoles/adverse effects ; Cystadenocarcinoma, Serous/enzymology ; Cystadenocarcinoma, Serous/pathology ; Doxorubicin/analogs & derivatives ; Doxorubicin/therapeutic use ; Fallopian Tube Neoplasms/enzymology ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; MAP Kinase Kinase 1/antagonists & inhibitors ; MAP Kinase Kinase 2/antagonists & inhibitors ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/drug therapy ; Ovarian Neoplasms/enzymology ; Ovarian Neoplasms/pathology ; Paclitaxel/therapeutic use ; Peritoneal Neoplasms/enzymology ; Peritoneal Neoplasms/pathology ; Polyethylene Glycols/therapeutic use ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Topotecan/therapeutic use ; Young Adult

المؤلفون: Oza AM; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Lorusso D; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, NY., Oaknin A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dean A; St John of God Subiaco Hospital, Subiaco, WA, Australia., Colombo N; University of Milan-Bicocca and European Institute of Oncology, Milan, Italy., Weberpals JI; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Clamp AR; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom., Scambia G; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Leary A; Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Villejuif, France., Holloway RW; AdventHealth Cancer Institute, Orlando, FL., Gancedo MA; Oncology Center of Galicia, Doctor Camilo Veiras, La Coruña, Spain., Fong PC; Auckland City Hospital, Auckland, New Zealand., Goh JC; Royal Brisbane and Women's Hospital and University of Queensland, St Lucia, Australia., O'Malley DM; The Ohio State University, James Cancer Center, Columbus, OH., Armstrong DK; Johns Hopkins University School of Medicine, Baltimore, MD., Banerjee S; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom., García-Donas J; HM Hospitales-Centro Integral Oncológico Hospital de Madrid Clara Campal, Madrid, Spain., Swisher EM; University of Washington, Seattle, WA., Cella D; Feinberg School of Medicine, Northwestern University, Chicago, IL., Meunier J; Modus Outcomes, Lyon, France., Goble S; Clovis Oncology, Inc., Boulder, CO., Cameron T; Clovis Oncology UK, Ltd., Cambridge, United Kingdom., Maloney L; Clovis Oncology, Inc., Boulder, CO., Mörk AC; Clovis Oncology Denmark, ApS, Copenhagen, Denmark., Bedel J; Clovis Oncology Switzerland, GmBH, Zurich, Switzerland., Ledermann JA; UCL Cancer Institute, University College London, and UCL Hospitals, London, United Kingdom., Coleman RL; The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Oct 20; Vol. 38 (30), pp. 3494-3505. Date of Electronic Publication: 2020 Aug 24.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Ovarian Epithelial/*drug therapy , Indoles/*therapeutic use , Neoplasm Recurrence, Local/*drug therapy , Ovarian Neoplasms/*drug therapy, Aged ; Clinical Trials, Phase III as Topic ; Double-Blind Method ; Female ; Humans ; Indoles/adverse effects ; Middle Aged ; Multicenter Studies as Topic ; Patient-Centered Care ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Progression-Free Survival ; Quality of Life ; Randomized Controlled Trials as Topic